1. The efficacy and safety of neoadjuvant nimotuzumab for gastric cancer
   Bin Cao et al, 2021, Medicine CrossRef
2. Gastric Cancer Signaling Pathways and Therapeutic Applications
   Mingfang Wu et al, 2024, Technology in Cancer Research & Treatment CrossRef
3. Inhibition of epithelial–mesenchymal transition by cetuximab via the EGFR‐GEP100‐Arf6‐AMAP1 pathway in head and neck cancer
   Yoshifumi Matsumoto et al, 2017, Head & Neck CrossRef
4. Investigational therapies targeting the ErbB family in oesophagogastric cancer
   Sing Yu Moorcraft et al, 2014, Expert Opinion on Investigational Drugs CrossRef
5. Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data
   Hiro Takahashi et al, 2013, Journal of Bioscience and Bioengineering CrossRef
6. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer
   Feng Du et al, 2015, Medicine CrossRef
7. Recombinant Protein (Luciferase-IgG Binding Domain) Conjugated Quantum Dots for BRET-Coupled Near-Infrared Imaging of Epidermal Growth Factor Receptors
   Setsuko Tsuboi et al, 2018, Bioconjugate Chemistry CrossRef
8. STAT3 is associated with lymph node metastasis in gastric cancer
   Jingyu Deng et al, 2013, Tumor Biology CrossRef
9. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
   Jun Taguchi et al, 2021, International Journal of Clinical Oncology CrossRef
10. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
    null null et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
11. Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing
    Bojana Stefanovska et al, 2020, Cancer Research CrossRef
12. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer
    Akira Ema et al, 2015, Cancer Medicine CrossRef
13. Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients
    FAN ZHANG et al, 2016, Oncology Letters CrossRef
14. Immunotherapy of Gastric and Esophageal Cancers
    Ali Sanjari-Moghaddam et al, 2020, Cancer Immunology CrossRef
15. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    Tom Waddell et al, 2013, The Lancet Oncology CrossRef
16. Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities
    Jinming Gu et al, 2015, PLOS ONE CrossRef
17. The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer
    Liu Hong et al, 2014, Expert Review of Gastroenterology & Hepatology CrossRef